Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is:
- To determine the maximum tolerated dose (MTD) of sunitinib when administered once weekly
or once every two weeks.
- To assess the safety and tolerability of sunitinib in a once weekly or once every two
weeks dose schedule.